NCT05868837View on ClinicalTrials.gov

Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)

PHASE3RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 28, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Myasthenia Gravis, Generalized
Interventions
DRUG

Rituximab

Rituximab 1000 mg IV on RCP days 1 and 15

OTHER

Placebo

Placebo 1000 mg IV on RCP days 1 and 15

Trial Locations (1)

00168

RECRUITING

Policlinico A. Gemelli IRCCS, Roma

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER